Assays and reference materials for current and future applications of heparins

Biologicals

Volumn 38, Issue 4, 2010, Pages 459-466

  Mulloy, B ^a   Hogwood, J ^a   Gray, E ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Heparan sulphate; Heparin; Low molecular weight heparin; Reference materials; Standards

Indexed keywords

AMYLOID BETA PROTEIN; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; FONDAPARINUX; HEPARAN SULFATE; HEPARIN; HEPARIN DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; L SELECTIN; LOW MOLECULAR WEIGHT HEPARIN; PADGEM PROTEIN; THROMBOCYTE FACTOR 4;

ALZHEIMER DISEASE; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ASTHMA; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MOLECULAR WEIGHT; NONHUMAN; OSTEOPOROSIS; PRIMARY PREVENTION; PRIORITY JOURNAL; PROLONGED PREGNANCY; PROTEIN EXPRESSION; REVIEW; STANDARD; STRUCTURE ACTIVITY RELATION; THROMBOSIS; TUMOR THROMBUS; ULCERATIVE COLITIS;

ANIMALS; ANTICOAGULANTS; BIOLOGICAL ASSAY; BLOOD COAGULATION; CARBOHYDRATE SEQUENCE; HEPARIN; HEPARITIN SULFATE; HUMANS; MOLECULAR SEQUENCE DATA; REFERENCE STANDARDS;

EID: 77955279756     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2010.02.010     Document Type: Review

References (87)

1. Gray E., Mulloy B., Barrowcliffe T.W. Heparin and low molecular weight heparin. Thromb Haemost 2008, 99:807-818.
2. Bishop J.R., Schuksz M., Esko J.D. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007, 446:1030-1037.
3. Stevens R.L., Adachi R. Protease-proteoglycan complexes of mouse and human mast cells and importance of their β-tryptase-heparin complexes in inflammation and innate immunity. Immunol Rev 2007, 217:155-167.
4. Petitou M., van Boeckel C.A. A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?. Angew Chem Int Ed Engl 2004, 43:3118-3133.
5. Nadanaka S., Kitagawa H. Heparan sulphate biosynthesis and disease. J Biochem 2008, 144:7-14.
6. Carlsson P., Presto J., Spillmann D., Lindahl U., Kjellen L. Heparin/heparan sulfate biosynthesis: processive formation of N-sulfated domains. J Biol Chem 2008, 283:20008-20014.
7. Merry C.L., Lyon M., Deakin J.A., Hopwood J.J., Gallagher J.T. Highly sensitive sequencing of the sulfated domains of heparan sulfate. J Biol Chem 1999, 274:18455-18462.
8. Mobli M., Nilsson M., Almond A. The structural plasticity of heparan sulfate NA-domains and hence their role in mediating multivalent interactions is confirmed by high-accuracy (15)N-NMR relaxation studies. Glycoconj J 2008, 25:401-414.
9. Stringer S.E., Forster M.J., Mulloy B., Bishop C.R., Graham G.J., Gallagher J.T. Characterization of the binding site on heparan sulfate for macrophage inflammatory protein 1a. Blood 2002, 100:1543-1550.
10. Yabe T., Shukla D., Spear P.G., Rosenberg R.D., Seeberger P.H., Shworak N.W. Portable sulphotransferase domain determines sequence specificity of heparin sulphate 3-O-sulphotransferases. Biochem J 2001, 359:235-241.
11. Guerrini M., Guglieri S., Naggi A., Sasisekharan R., Torri G. Low molecular weight heparins: structural differentiation by bidimensional nuclear magnetic resonance spectroscopy. Semin Thromb Hemost 2007, 33:478-487.
12. Hamel D.J., Sielaff I., Proudfoot A.E., Handel T.M. Chapter 4. Interactions of chemokines with glycosaminoglycans. Methods Enzymol 2009, 461:71-102.
13. Coombe D.R. Biological implications of glycosaminoglycan interactions with haemopoietic cytokines. Immunol Cell Biol 2008, 86:598-607.
14. Borsig L. Antimetastatic activities of modified heparins: selectin inhibition by heparin attenuates metastasis. Semin Thromb Hemost 2007, 33:540-546.
15. Milner C.M., Higman V.A., Day A.J. TSG-6: a pluripotent inflammatory mediator?. Biochem Soc Trans 2006, 34:446-450.
16. Fukuhara N., Howitt J.A., Hussain S.-A., Hohenester E. Structural and functional analysis of slit and heparin binding to immunoglobulin-like domains 1 and 2 of Drosophila Robo. J Biol Chem 2008, 283:16226-16234.
17. Harmer N. Insights into the role of heparan sulphate in fibroblast growth factor signalling. Biochem Soc Trans 2006, 34:442-445.
18. Lundkvist A., Lee S., Iruela-Arispe L., Betsholtz C., Gerhardt H. Growth factor gradients in vascular patterning. Novartis Found Symp 2007, 283:194-201.
19. Mulloy B., Gray E., Barrowcliffe T.W. Characterization of unfractionated heparin: comparison of materials from the last 50 years. Thromb Haemost 2000, 84:1052-1056.
20. Mulloy B., Gee C., Wheeler S., Wait R., Thomas S., Gray E., et al. Molecular weight measurements of low molecular weight heparins by gel permeation chromatography. Thromb Haemost 1997, 77:668-674.
21. Ph. Eur 01/2008:0828 Heparins, Low-Molecular-Mass.
22. Huntington J.A. Shape-shifting serpins - advantages of a mobile mechanism. Trends Biochem Sci 2006, 3:427-435.
23. Eur Pharm 6.0 01/2008:20705 Assay of heparin.
24. Gray E., Walker A.D., Mulloy B., Barrowcliffe T.W. A collaborative study to establish the 5th International Standard for Unfractionated Heparin. Thromb Haemost 2000, 84:1017-1022.
25. Gray E., Rigsby P., Behr-Gross M.E. Collaborative study to establish the low-molecular-mass heparin for assay - European Pharmacopoeia Biological Reference Preparation. Pharmeuropa Bio 2004, 1:59-76.
26. Rajgopal R., Bear M., Butcher M.K., Shaughnessy S.G. The effects of heparin and low molecular weight heparin on bone. Thromb Res 2008, 122:293-298.
27. Veverka V., Henry A.J., Slocombe P.M., Ventom A., Mulloy B., Muskett F.W., et al. Characterisation of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem 2009, 284:10890-10900.
28. Rauova L., Poncz M., McKenzie S., Reilly M.P., Arepally G., Weisel J. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 2005, 105:131-138.
29. Ahmed T., Garrigo J., Danta I. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N Engl J Med 1993, 329:90-95.
30. Ledson M., Gallagher M., Hart C.A., Walshaw M.J. Nebulized heparin in Burkholderia cepacia colonised adult cystic fibrosis patients. Eur Respir J 2001, 17:36-38.
31. Bergamaschini L., Rossi E., Storini C., Pizzimenti S., Distaso M., Perego C., et al. Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and β-amyloid accumulation in a mouse model of Alzheimer's disease. J Neurosci 2004, 24:4181-4186.
32. Papa A., Danese S., Gasbarrini A., Gasbarrini G. Potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease. Aliment Pharmacol Ther 2000, 14:1403-1409.
33. Kreuger J., Spillmann D., Li J.P., Lindahl U. Interactions between heparan sulfate and proteins: the concept of specificity. J Cell Biol 2006, 174:323-327.
34. Casu B., Vlodavsky A., Sanderson R.D. Non-anticoagulant heparin and inhibition of cancer. Pathophysiol Haemost Thromb 2008, 36:195-203.
35. Young E. The anti-inflammatory effects of heparin and related compounds. Thromb Res 2008, 112:734-752.
36. Skidmore M.A., Dumax-Vorzet A.F., Guimond S.E., Rudd T.R., Edwards E.A., Turnbull J.E., et al. Disruption of resetting in Plasmodium falciparum with chemically modified heparin and low molecular weight heparin derivatives possessing reduced anticoagulant and other serine protease inhibition activities. J Med Chem 2008, 51:1453-1458.
37. Kanabar V., Page C.P., Simcock D.E., Karner C., Mahn K., O'Connor B.J., et al. Heparin and structurally related polymers attenuate eotaxin-1 (CCL11) release from human airway smooth muscle. Br J Pharmacol 2008, 154:833-842.
38. Fryer A., Huang Y.-C., Rao G., Jacoby D., Mancilla E., Whorton R., et al. Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung. J Pharmacol Exp Ther 1997, 282:208-219.
39. King M., Rub B.K. Pharmacologic approaches to discovery and development of new mucolytic agents. Adv Drug Deliv Rev. 2002, 54:1475-1490.
40. Hudson M., Chitolie A., Hutton R.A., Smith M.S.H., Pounder R.E., Wakefield A.J. Thrombotic vascular risk factors in inflammatory bowel disease. Gut 1996, 38:733-737.
41. Nelson R.M., Cecconi O., Roberts W.G., Aruffo A., Linhardt R.J., Bevilacqua M.P. Heparin oligosaccharides bind L- and P-Selectin and inhibit acute inflammation. Blood 1993, 82:3253-3258.
42. Miller S.J., Hoggat A.M., Faulk W.P. Heparin regulates ICAM-1 expression in human endothelial cells: an example of non-cytokine-mediated endothelial activation. Thromb Haemost 1998, 80:481-487.
43. Wang L., Brown J.R., Varki A., Esko J.D. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest 2002, 110:127-136.
44. Derhaschnig U., Pernerstorfer T., Knechtelsdorfer M., Hollenstein U., Panzer S., Jilma B. Evaluation of anti-inflammatory and anti-adhesive effects of heparin in endotoxemia. Crit Care Med 2003, 31:1108-1112.
45. Tossavainen H., Pihlajamaa T., Huttunen T.K., Raulo E., Rauvala H., Permi P., et al. The layered fold of the TSR domain of P. falciparum TRAP contains a heparin binding site. Protein Sci 2006, 15:1760-1768.
46. Vogt A.M., Pettersson F., Moll K., Jonsson C., Normark J., Ribacke U., et al. Release of sequestered malaria parasites upon injection of a glycosaminoglycan. PLoS Pathog 2006, 2:e100.
47. Havlik I., Looareesuwan S., Vannaphan S., Wilairatana P., Krudsood S., Thuma P.E., et al. Curdlan sulphate in human severe/cerebral Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 2005, 99:333-340.
48. Copeland R., Balasubramaniam A., Tiwari V., Zhang F., Bridges A., Linhardt R.J., et al. Using a 3-O-sulfated heparin octasaccharide to inhibit the entry of herpes simplex virus type 1. Biochemistry 2008, 47:5774-5783.
49. de Agostini A.I., Dong J.C., de Vantéry Arrighi C., Ramus M.A., Dentand-Quadri I., Thalmann S., et al. Human follicular fluid heparan sulfate contains abundant 3-O-sulfated chains with anticoagulant activity. J Biol Chem 2008, 283:28115-28124.
50. Shworak N.W., HajMohammadi S., de Agostini A.I., Rosenberg R.D. Mice deficient in heparan sulfate 3-O-sulfotransferase-1: normal hemostasis with unexpected perinatal phenotypes. Glycoconj J 2002, 9:355-361.
51. Hellgren M., Andersson E., Byström B., Edlund M., Holmberg A., Klimavicute A., et al. Dalteparin shortens human labor. J Thromb Haemostas 2007, 5(Suppl. 2). P-M-609.
52. http://clinicaltrials.gov/show/NCT00710242.
53. Sennström M.B., Ekman G., Westerggren-Thorsson G., Malmstrom A., Byström B., Endresen U., et al. Human cervical ripening, an inflammatory process mediated by cytokines. Mol Hum Reprod 2000, 6:375-381.
54. Osman I., Yound A., Ledingham M.A., Thomson A.J., Jordan F., Greer I.A., et al. Leukocyte density and pro-inflammatory cytokine expression in human fetal membranes, deciduas, cervix and myometrium before and during labour at term. Mol Hum Reprod 2003, 9:41-45.
55. Mellor P., Harvey J.R., Murphy K.J., Pye D., O'Boyle G., Lennard T.W.J., et al. Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo. Br J Cancer 2002, 97:761-768.
56. Wei M., Tai G., Gao Y., Huang B., Zhou Y., Hao S., et al. Modified heparin inhibits P-selectin-mediated cell adhesion of human colon carcinoma cells to immobilized platelets under dynamic flow conditions. J Biol Chem 2004, 279:29202-29210.
57. Korir A.K., Larive C.K. Advances in the separation, sensitive detection, and characterization of heparin and heparan sulfate. Anal Bioanal Chem 2009, 393:155-169.
58. Ph. Eur. 01/2008:1097 Enoxaparin sodium; Ph. Eur. 01/2008:1134; Nadroparin calcium; Ph. Eur. 01/2008:1195 Dalteparin sodium; Ph. Eur. 01/2008:1252 Parnaparin sodium; Ph. Eur. 01/2008:1271 Tinzaparin sodium.
59. Adams T.E., Huntington J.A. Thrombin-cofactor interactions: structural insights into regulatory mechanisms. Arterioscler Thromb Vasc Biol 2006, 26:1738-1745.
60. Al Dieri R., Wagenvoord R., van Dedem G.W.K., Beguin S., Hemker H.C. The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif - the C-domain. J Thromb Haemost 2003, 1:907-914.
61. Mulloy B. Gel permeation chromatography of heparin. Analytical techniques to evaluate the structure and function of natural polysaccharides: glycosaminoglycans 2002, 115-128. Research Signpost, Trivandrum. N. Volpi (Ed.).
62. Buzzega D., Maccari F., Volpi N. Fluorophore-assisted carbohydrate electrophoresis for the determination of molecular mass of heparins and low-molecular-weight (LMW) heparins. Electrophoresis 2008, 29:4192-4202.
63. Pavlov G., Finet S., Tatarenko K., Korneeva E., Ebel C. Conformation of heparin studied with macromolecular hydrodynamic methods and X-ray scattering. Eur Biophys J 2003, 32:437-449.
64. Sitkowski J., Bednarek E., Bocian W., Kozerski L. Assessment of oversulfated chondroitin sulfate in low molecular weight and unfractioned heparins diffusion ordered nuclear magnetic resonance spectroscopy method. J Med Chem 2008, 51:7663-7665.
65. Bertini S., Bisio A., Torri G., Bensi D., Terbojevich M. Molecular weight determination of heparin and dermatan sulfate by size exclusion chromatography with a triple detector array. Biomacromolecules 2005, 6:168-173.
66. Volpi N., Bolognani L. Glycosaminoglycans and proteins: different behaviours in high-performance size-exclusion chromatography. J Chromatogr 1993, 630:390-396.
67. Nielsen J.I. A convenient method for molecular mass determination of heparin. Thromb Haemost 1992, 68:478-480.
68. Mulloy B., Heath A., Behr-Gross M.-E. Establishment of replacement batches for heparin low-molecular-mass for Calibration CRS, and the International Standard Low Molecular Weight Heparin for Calibration. Pharmeuropa 2007, 1:29-48.
69. Jiménez-Barbero J., Díaz M.D., Nieto P.M. NMR structural studies of oligosaccharides related to cancer processes. Anticancer Agents Med Chem 2008, 8:52-63.
70. Wang Y., Xin D., Liu K., Xiang J. Heparin-paclitaxel conjugates using mixed anhydride as intermediate: synthesis, influence of polymer structure on drug release, anticoagulant activity and in vitro efficiency. Pharm Res 2009, 26:785-793.
71. Beyer T., Diehl B., Randel G., Humpfer E., Schäfer H., Spraul M., et al. Quality assessment of unfractionated heparin using 1H nuclear magnetic resonance spectroscopy. J Pharm Biomed Anal 2008, 48:13-19.
72. 1H-NMR. Pharmeuropa Bio 2008, 1:31-39.
73. Longstaff C., Whitton C.M., Stebbings R., Gray E. How do we assure the quality of biological medicines?. Drug Discov Today 2009, 14:50-55.
74. Pharmacopoeial Forum 2009, 35(5). Heparin Sodium.
75. 1H NMR spectroscopy. J Pharm Biomed Anal 2009, 49:1060-1064.
76. Viola M., Vigetti D., Karousou E., Bartolini B., Genasetti A., Rizzi M., et al. New electrophoretic and chromatographic techniques for analysis of heparin and heparan sulfate. Electrophoresis 2008, 29:3168-3174.
77. Volpi N., Maccari F., Linhardt R.J. Capillary electrophoresis of complex natural polysaccharides. Electrophoresis 2008, 29:3095-3106.
78. Zaia J. On-line separations combined with MS for analysis of glycosaminoglycans. Mass Spectrom Rev 2009, 28:254-272.
79. Korir A.K., Limtiaco J.F.K., Gutierrez S.M., Larive C.K. Ultraperformance ion-pair liquid chromatography coupled to electrospray time-of-flight mass spectrometry for compositional profiling and quantification of heparin and heparan sulphate. Anal Chem 2009, 80:1297-1306.
80. Doneanu C.E., Chen W., Gebler J.C. Analysis of oligosaccharides derived from heparin by ion-pair reversed-phase chromatography/mass spectrometry. Anal Chem 2009, 81:3485-3499.
81. Houiste C., Auguste C., Macrez C., Dereux S., Derouet A., Anger P. Quantitative PCR and disaccharide profiling to characterize the animal origin of low-molecular-weight heparins. Clin Appl Thromb Hemost 2009, 15:50-58.
82. Zhang Z., Xie J., Liu J., Linhardt R.J. Quantification of heparan sulfate disaccharides using ion-pairing reversed-phase microflow high-performance liquid chromatography with electrospray ionization trap mass spectrometry. Anal Chem 2009, 81:4349-4355.
83. Lever R., Lo W.T., Faraidoun M., Amin V., Brown R.A., Gallagher J., et al. Size-fractionated heparins have differential effects on human neutrophil function in vitro. Br J Pharmacol 2007, 151:837-843.
84. Spencer J.L., Stone P.J., Nugent M.A. New insights into the inhibition of human neutrophil elastase by heparin. Biochemistry 2006, 45:9104-9120.
85. Schorr K., Rott A., Da Costa F., Merfort I. Optimisation of a human neutrophil elastase assay and investigation of the effect of sesquiterpene lactones. Biologicals 2005, 33:175-184.
86. Groth I., Alban S. Elastase inhibition assay with peptide substrates - an example for the limited comparability of in vitro results. Planta Med 2008, 74:852-858.
87. Groth I., Grünewald N., Alban S. Pharmacological profiles of animal- and nonanimal-derived sulfated polysaccharides - comparison of unfractionated heparin, the semisynthetic glucan sulfate PS3, and the sulfated polysaccharide fraction isolated from Delesseria sanguinea. Glycobiology 2009, 19:408-417.